MiNK Therapeutics (NASDAQ:INKT) Receives “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of MiNK Therapeutics (NASDAQ:INKT) in a research note published on Friday,Benzinga reports. The brokerage currently has a $9.00 price target on the stock. HC Wainwright also issued estimates for MiNK Therapeutics’ FY2028 earnings at $0.24 EPS.

Separately, Robert W. Baird lowered their price objective on shares of MiNK Therapeutics from $8.00 to $4.00 and set an “outperform” rating for the company in a research note on Friday.

MiNK Therapeutics Stock Up 0.5 %

Shares of NASDAQ INKT opened at $0.75 on Friday. MiNK Therapeutics has a twelve month low of $0.57 and a twelve month high of $1.90. The firm has a market cap of $29.81 million, a PE ratio of -1.93 and a beta of 0.05. The business has a fifty day simple moving average of $0.73 and a two-hundred day simple moving average of $0.85.

Hedge Funds Weigh In On MiNK Therapeutics

An institutional investor recently raised its position in MiNK Therapeutics stock. Renaissance Technologies LLC lifted its stake in MiNK Therapeutics, Inc. (NASDAQ:INKT) by 21.5% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 127,841 shares of the company’s stock after acquiring an additional 22,613 shares during the period. Renaissance Technologies LLC owned 0.37% of MiNK Therapeutics worth $121,000 at the end of the most recent quarter. 2.87% of the stock is owned by institutional investors.

About MiNK Therapeutics

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.